These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? Smith MR; O'Malley AJ; Keating NL BJU Int; 2008 Jun; 101(11):1335-6. PubMed ID: 18454791 [No Abstract] [Full Text] [Related]
26. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Saylor PJ; Keating NL; Freedland SJ; Smith MR Drugs; 2011 Feb; 71(3):255-61. PubMed ID: 21319864 [TBL] [Abstract][Full Text] [Related]
27. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved. Azvolinsky A J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000 [No Abstract] [Full Text] [Related]
28. Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system? Zhang K; Zhang L; Hao Z; Liang C World J Urol; 2016 Jun; 34(6):879-81. PubMed ID: 26424563 [No Abstract] [Full Text] [Related]
30. Androgen deprivation treatment in prostate cancer. Thomas BC; Neal DE BMJ; 2013 Jan; 346():e8555. PubMed ID: 23303885 [No Abstract] [Full Text] [Related]
31. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711 [TBL] [Abstract][Full Text] [Related]
32. Management of metastatic hormone-sensitive prostate cancer. Bernard B; Sweeney CJ Curr Urol Rep; 2015 Mar; 16(3):14. PubMed ID: 25677237 [TBL] [Abstract][Full Text] [Related]
33. Prostate cancer drugs. Making sense of the options. Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308 [No Abstract] [Full Text] [Related]
34. New-onset psychosis following androgen deprivation therapy for prostate cancer. Bernad DM; Dal Pra A; Baule C; Frey BN; Faria S Can J Urol; 2013 Aug; 20(4):6868-70. PubMed ID: 23930615 [TBL] [Abstract][Full Text] [Related]
35. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy. Leahy Y Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533 [TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Freedland SJ; Eastham J; Shore N Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933 [TBL] [Abstract][Full Text] [Related]
38. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer. Harrington JM; Schwenke DC; Epstein DR; Bailey DE Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236 [TBL] [Abstract][Full Text] [Related]
39. Minimizing the risk of sarcopenic obesity during androgen deprivation therapy-promising results for men treated with GnRH antagonists. Csizmadi I Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):589-590. PubMed ID: 33820952 [No Abstract] [Full Text] [Related]
40. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Smith MR Curr Urol Rep; 2008 May; 9(3):197-202. PubMed ID: 18765113 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]